[{"from": "human", "value": "Could you provide a description of this molecule? [C][C][C][=C][C][N][C][=Branch2][#Branch2][=C][=C][C][=C][Branch1][Branch1][C][Ring1][=Branch1][=O][C][O][C][=Branch1][C][=O][C@@][Ring1][=Branch2][Branch1][Ring1][C][C][O][C][=Branch1][C][=O][O][C][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][N][C][=Branch1][C][=O][C@H1][Branch1][=Branch1][C][C][C][C][N][N][C][=Branch1][C][=O][C][O][C][C][=Branch1][C][=O][N][C][C][O][C][C][O][C][C][O][C][C][O][C][C][O][C][C][O][C][C][O][C][C][O][C][C][N][C][=C][Branch1][Branch1][N][=N][Ring1][Branch1][C][N][C][=Branch1][C][=O][C][C][C][C][Branch1][Branch1][C][C][Ring1][=Branch1][C][N][C][=Branch1][C][=O][C][C][Branch1][Branch1][C][Ring1][=Branch1][=O][S][C][C@@H1][Branch1][=Branch1][C][=Branch1][C][=O][O][N][C][Ring2][Branch2][=Branch1][=N][C][=C][Ring2][Branch2][#Branch2][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O]"}, {"from": "gpt", "value": "The molecule is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2 (TROP-2) antibody with the topoisomerase I inhibitor SN-38.  Sacituzumab govitecan was granted FDA approval on April 22nd, 2020 and is marketed under the brand name Trodelvy\u2122 by Immunomedics, Inc.; it is currently indicated under accelerated approval for the treatment of mTNBC patients who have undergone two or more prior therapies. As a targeted cytotoxic agent, it is hoped to provide similar efficacy with reduced adverse effects. In November 2021, sacituzumab govitecan was also approved by the European Commission."}]